Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Mapping Immune Landscapes in Minimally and Highly Invasive Brain Metastases

FY 2024-25

Summary
Brain metastases (BrM) affect about 30% of patients with advanced cancers, commonly originating from the lung, breast, or skin. While the brain was once though to be sequestered from immune responses, recent studies have shown that immune cells can indeed infiltrate BrM. This has led to trials of using medication (immune checkpoint inhibitors; ICI) that release the brakes of the immune system to allow for anti-tumor activity. However, only some patients benefit from ICI, and many experience severe side effects, highlighting the need to identify who may be better responders to this therapy.My research focuses on two distinct types of BrM based on their growth patterns. Minimally invasive (MI) BrM form clear boundaries with the brain, while highly invasive (HI) BrM spread aggressively into surrounding tissue. Patients with HI BrM face worse outcomes, including higher recurrence and shorter survival following surgical tumor removal. I hypothesize that these MI BrM have an immune cell-rich environment that makes them more responsive to immune-activating medication, while HI BrM lack the necessary immune cell infiltration for this therapy to work.To test this, I will first analyze immune cells in human MI and HI BrM using advanced imaging techniques. This will reveal how many immune cells are in these BrM, and how they are distributed. Next, I will develop a mouse model that mimics human MI and HI BrM to study their immune environments in a more controlled setting to better understand human disease. Finally, I will test whether mice with MI and HI BrM respond differently to ICI.By identifying biomarkers that predict treatment success, we hope to improve therapies for patients with BrM, offering a path toward more effective and personalized care.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530332
Name
Aghazadeh Habashi Yashar
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mapping Immune Landscapes in Minimally and Highly Invasive Brain Metastases
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Metastasis; Highly Invasive; Imaging Mass Cytometry; Immune Landscape; Lymphoid Cells; Minimally Invasive; Myeloid Cells
Abstract
Brain metastases (BrM) affect about 30% of patients with advanced cancers, commonly originating from the lung, breast, or skin. While the brain was once though to be sequestered from immune responses, recent studies have shown that immune cells can indeed infiltrate BrM. This has led to trials of using medication (immune checkpoint inhibitors; ICI) that release the brakes of the immune system to allow for anti-tumor activity. However, only some patients benefit from ICI, and many experience severe side effects, highlighting the need to identify who may be better responders to this therapy.My research focuses on two distinct types of BrM based on their growth patterns. Minimally invasive (MI) BrM form clear boundaries with the brain, while highly invasive (HI) BrM spread aggressively into surrounding tissue. Patients with HI BrM face worse outcomes, including higher recurrence and shorter survival following surgical tumor removal. I hypothesize that these MI BrM have an immune cell-rich environment that makes them more responsive to immune-activating medication, while HI BrM lack the necessary immune cell infiltration for this therapy to work.To test this, I will first analyze immune cells in human MI and HI BrM using advanced imaging techniques. This will reveal how many immune cells are in these BrM, and how they are distributed. Next, I will develop a mouse model that mimics human MI and HI BrM to study their immune environments in a more controlled setting to better understand human disease. Finally, I will test whether mice with MI and HI BrM respond differently to ICI.By identifying biomarkers that predict treatment success, we hope to improve therapies for patients with BrM, offering a path toward more effective and personalized care.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Aghazadeh Habashi, Yashar
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~